Tryptamine Therapeutics Ltd

TYP

Company Profile

  • Business description

    Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

  • Contact

    C/o Bio101 Financial Advisory Pty Ltd
    697 Burke Road, Suite 201
    Camberwell
    MelbourneVIC3124
    AUS

    T: +61 390920475

    https://www.tryptherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    50

Stocks News & Analysis

stocks

Microsoft earnings: Strong, including Azure, but overall guidance is in line

We think Microsoft stock is moderately undervalued.
stocks

After earnings, is Tesla stock a buy, a sell, or fairly valued?

Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
stocks

3 cheap fully franked stocks

Well priced Aussie shares that offer a tax rebate.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,206.7032.800.36%
CAC 408,147.3553.53-0.65%
DAX 4024,118.895.32-0.02%
Dow JONES (US)47,522.12109.88-0.23%
FTSE 1009,721.0635.08-0.36%
HKSE26,282.6963.45-0.24%
NASDAQ23,581.14377.33-1.57%
Nikkei 22551,325.6117.960.04%
NZX 50 Index13,498.3639.070.29%
S&P 5006,822.3468.25-0.99%
S&P/ASX 2008,913.2033.200.37%
SSE Composite Index3,986.9029.43-0.73%

Market Movers